Tyloxapol: Difference between revisions
Content deleted Content added
m Stub sorting and placement of stub template(s) |
Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation ( |
||
| Line 1: | Line 1: | ||
{{Unreferenced stub|auto=yes|date=December 2009}} |
{{Unreferenced stub|auto=yes|date=December 2009}} |
||
{{Drugbox |
{{Drugbox |
||
| verifiedrevid = 376126506 |
|||
| IUPAC_name = |
| IUPAC_name = |
||
| image = Tyloxapol.png |
| image = Tyloxapol.png |
||
Revision as of 14:22, 18 April 2011
 |
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.209.660 |
| Chemical and physical data | |
| Formula | (C15H21O(C2H4O)m)n |
| Molar mass | variable |
| (verify) | |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |